<?xml version="1.0" encoding="UTF-8"?>
<p>Modulation of the activity of a specific enzyme or receptor by a small molecule is one of the cornerstones of modern target-based drug discovery. However, small molecules frequently bind to multiple target molecules, influencing both drug efficacy and safety [
 <xref rid="B15-molecules-25-04077" ref-type="bibr">15</xref>,
 <xref rid="B16-molecules-25-04077" ref-type="bibr">16</xref>]. Although the one-drug-hits-one target approach was dominant in the post-genomic era, it is regarded as inadequate to address complex diseases [
 <xref rid="B17-molecules-25-04077" ref-type="bibr">17</xref>]. The multitarget approach has become a fruitful area of drug discovery, particularly in developing medicines to treat major complex diseases. For example, natural products such as genistein [
 <xref rid="B18-molecules-25-04077" ref-type="bibr">18</xref>], curcumin, and tashinone [
 <xref rid="B19-molecules-25-04077" ref-type="bibr">19</xref>] have been reported to inhibit amyloid β (Aβ) and human islet amylin (hIAPP) associated with type 2 diabetes. Another compound, miltirone, isolated from 
 <italic>Salvia miltiorrhiza</italic>, was shown to be a dual inhibitor of P-glycoprotein and cell growth in doxorubicin-resistant HepG2 cells [
 <xref rid="B20-molecules-25-04077" ref-type="bibr">20</xref>]. Furthermore, cannabinoid compounds, which are structurally related to DCA, have been reported to inhibit the formation of Aβ fibrils and aggregates, which have neuronal and microglial-activated neurotoxicity [
 <xref rid="B21-molecules-25-04077" ref-type="bibr">21</xref>].
</p>
